

European Commission Initiative on Breast Cancer

Annual Declaration of Interests (ADoI)

Name:

[Please copy rows as needed for subsequent or parallel activities of the same nature]

[If it is not clear to you under which category of the form to declare an interest, you can declare it under "Other"].

Nature of activities	Period	Entity	Subject matter
1. Ownership or financial investments, including shares	NONE	NONE	NONE
2. Membership of a managing body or equivalent structure	NONE	NONE	NONE
3. Membership of another scientific advisory body	Since more than 5 years up to date	<ul style="list-style-type: none"> - European association for Palliative Care Research Network (EAPC RN) - Milano National Cancer Institute - Non profit organization and NGO 	Function of body: Promote palliative care research; Organization of EAPC research conference Function of expert: Chair Link to website of body: https://www.eapcnet.eu/ Responsible of cancer pain guidelines working group for EAPC RN and PRC (see below)
	Since more than 5 years up to date	<ul style="list-style-type: none"> -European Palliative Care Research Center (PRC) - Norwegian University for Science and Technology Trondheim 	Function of body : Promote clinical trials in palliative care Function : Clinical investigator, Advisor Link to website of body : www.ntnu.edu/prc

Nature of activities	Period	Entity	Subject matter
	Since more than 5 years up to 31/12/2016	<ul style="list-style-type: none"> -Scientific Committee of Floriani Foundation - Milan - Non profit public foundation 	<p>Function of body : Promote palliative care and fund palliative care activities including research Link to website of body : www.fondazionefloriani.eu</p>
4. Employment	09/07/2006 up to date	<ul style="list-style-type: none"> - Fondazione IRCCS Istituto Nazionale dei Tumori - Milano (Italy) -Type: Public hospital and national health care system. <p>Cancer research and referral institution</p>	<p>Director of the clinical and scientific activities of the Palliative Care, Pain Therapy and Rehabilitation department</p>
	09/2010 up to 2018	<ul style="list-style-type: none"> -Norwegian University of Science and Technology (NTNU) - Trondheim, Norway 	<p>Part-time Associate Professor of Palliative Medicine</p>
5. Consultancy/Advisory	06/11/2019	<ul style="list-style-type: none"> - Angelini (Milano, Italy) -Pharmaceutical Company - 1500 e 	<p>Advisor for the workshop on Breakthrough Cancer Pain Management</p>
	02/10/2019	<ul style="list-style-type: none"> - Shionogy ; Molteni (Roma, Italy) - Pharmaceutical Companies - 750 e 	<p>Advisor on OIC management in chronic pain patients</p>
	07/2019 – 11/2019	<ul style="list-style-type: none"> -Kyowa Kirin (Bologna, Italy) - Pharmaceutical Company - 2500 e 	<p>Advisor on OIC and OIBD management</p>
	11/2016	<p>Institute de Recherche « Pierre Fabre » (Boulogne, France) 2400 e</p>	<p>Advisory board meetings to develop clinical trials on cancer pan</p>

Nature of activities	Period	Entity	Subject matter
	09/2016	Sandoz International GmbH (Barleben, Germany) Pharmaceutical Company 1000 e	Editor for educational newsletter
	13-14/11/2015	Italfarmaco (Cinisello Balsamo, Milano, Italy) Pharmaceutical Company 800 e	Speaker at education course
	12/2014	Pfizer (New York, USA) Pharmaceutical Company 4000 e	Advisory board meetings to develop clinical trials on cancer pain
	10-12/10/2014	Molteni & C Soc Esercizio Spa (Scandicci, Firenze, Italy) Pharmaceutical Company 1000 e	Advisor in organizing professional education and scientific meetings on cancer pain
	27/09/2014	Helsin Healthcare (Lugano, Switzerland) Pharmaceutical Company 1500 e	Advisor for anorexia syndrome
	03/2014	-Gruenthal GmbH (Aachen, Germany) Pharmaceutical Company 1000 e	Preparation of scientific material for cancer pain education
6. Influence on definition of research priorities	NONE	NONE	NONE

Nature of activities	Period	Entity	Subject matter
7. Research grants and other funding	01/2015-12/2017	- AIRC (Italian Association for Cancer Research) - Private ONLUS org. - 276,000 e to Institution	Principal Investigator of the MOLO study on genetic and clinical variability of the response of cancer pain to opioid pharmacotherapy
	11/2014-11/2017	National finalized research fund of the Italian Ministry of Health 77,400 e to Institution	Application of early palliative care in advanced pancreas and gastric cancer – workpackage leader
	09/2015-09/2019	Molteni & C Soc Esercizio Spa 7000 e institutional funding	IOPS study II on breakthrough cancer pain
	In the last 5 years	The following companies : Prokstrakan, Gruenenthal GmbH, Amgen gave unrestricted grants to my institution for a total of 40,000 e	Funds were employed in independent research activities on cancer pain and palliative care
	Since 2015 up to 2019	Ipsen Total amount will depend on the n. of patients enrolled at the end of the study period	Pharmacological clinical trial on the effect of lanreotide in the management of malignant bowel obstruction
8. Principal investigator or investigator	SEE ABOVE	SEE ABOVE	SEE ABOVE
9. Intellectual property rights (IPR)	NOT RELEVANT	NOT RELEVANT	NOT RELEVANT
10. Other membership or affiliation	NOT RELEVANT	NOT RELEVANT	NOT RELEVANT
11. Interests of others	NONE	NONE	NONE

Nature of activities	Period	Entity	Subject matter
12. Other	NONE	NONE	NONE

I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge. Should there be any change to the above information, I will promptly notify the responsible service of the Commission and complete a new DoI form including the changes.

Done at: MILAN Date: 16/12/2019

Signature: 